The Best Psychedelic for PTSD? Comparing MDMA, Psilocybin, and Ketamine

If you are researching the best psychedelic for PTSD, you are likely running into a frustrating gap between what the science supports and what you can actually access. The compound with the deepest evidence base is the one you cannot legally get. The compound you can get has thinner evidence for trauma specifically. And the compound generating the most public excitement is, for PTSD, still years behind where most headlines imply.

This post lays out what each of the three main candidates actually shows, where the evidence is strong and where it is thin, and how the differences translate into a real decision for someone weighing options right now.

Why PTSD Is Different from Depression

It is tempting to treat the psychedelic evidence base as one body of research. It is not. A compound that performs well against depression will not necessarily perform well against trauma, because the two conditions ask different things of a treatment.

Depression tends to involve a locked-in negative self-narrative and reduced cognitive flexibility. Compounds that loosen rigid thought patterns, psilocybin most notably, have a plausible route to helping. PTSD is different. It involves a fear memory that the nervous system has failed to file away as past, so the body keeps responding as though the threat is present. Treating it usually requires the person to approach the memory directly without being overwhelmed by it, which is the exact thing trauma makes difficult.

This distinction matters because it explains why MDMA, which is not a classic psychedelic at all, has outperformed compounds with far more cultural cachet in the trauma space. MDMA reduces the fear response enough that the memory becomes approachable. That is a different mechanism than perceptual or mystical experience, and for PTSD it appears to be the more relevant one.

MDMA for PTSD: The Strongest Evidence, the Hardest Access

MDMA-assisted therapy is the only psychedelic treatment for PTSD to complete two Phase 3 trials. In MAPP1, published in Nature Medicine in 2021, 67 percent of participants who received MDMA-assisted therapy no longer met criteria for a PTSD diagnosis after three sessions, compared with 32 percent in the placebo-with-therapy group. The confirmatory trial, MAPP2, reported similar results: 71.2 percent of the MDMA group no longer met diagnostic criteria, versus 47.6 percent on placebo with therapy.

Two aspects of these trials deserve attention beyond the headline numbers.

The first is dropout. Standard trauma therapies lose a substantial share of patients before completion. One comparison study in veterans reported dropout rates approaching half for prolonged exposure and cognitive processing therapy. The MDMA trials saw far lower dropout, which suggests the treatment is not simply more effective but more tolerable to sit through. For someone who has already abandoned one course of trauma therapy because the sessions were unbearable, that is not a footnote.

The second is what MDMA-assisted therapy actually is. It is not a drug administered in isolation. The protocol involves preparatory sessions, two or three long dosing sessions with two therapists present, and structured integration afterward. The therapy is not a wrapper around the drug. It is half the treatment.

Here is where things get difficult. In August 2024, the FDA declined to approve MDMA-assisted therapy, citing concerns about functional unblinding, safety data collection, and trial conduct. That decision did not overturn the efficacy findings, but it did mean that the strongest evidence base in the field currently supports a treatment that is not legally available in the United States. Additional trials are being designed to address the FDA’s concerns, but approval is not imminent.

Ketamine for PTSD: Legally Available, More Modest Effects

Ketamine occupies the opposite position. Its evidence for trauma is thinner than MDMA’s, but it is the only option a person in most states can legally access through a licensed provider today.

The research is real, if smaller in scale. A 2014 randomized trial in JAMA Psychiatry provided the first evidence that a single intravenous ketamine infusion could produce rapid reductions in PTSD symptom severity within 24 hours. A follow-up randomized controlled trial published in the American Journal of Psychiatry in 2021 tested repeated infusions, six over two weeks, against an active placebo, and found significant reductions in symptom severity for the ketamine group. These are meaningful findings. They are also based on small samples, and the field has not yet produced a large multi-site trial of the kind MDMA has completed.

The more important limitation is durability. Ketamine’s effects on trauma symptoms tend to fade over weeks rather than persisting for months, which is why clinics typically use a series of infusions followed by maintenance sessions. Compare that with MDMA, where the therapeutic model aims for durable change after two or three sessions and then stops.

What we can say with confidence is that ketamine is best understood as a treatment that opens a window rather than one that closes a chapter. It reduces symptom load and creates a period of increased psychological flexibility. Whether that window gets used well depends almost entirely on what surrounds it. Ketamine paired with skilled trauma-informed therapy is a serious intervention. Ketamine administered in a clinic that hands you headphones and books you again in a week is something considerably less.

For a fuller picture of how ketamine is delivered and what settings differ, our overview of psilocybin and ketamine therapy compared covers the practical differences in more depth.

Psilocybin for PTSD: Promising, Early, and Frequently Overstated

Psilocybin has the strongest evidence of any classic psychedelic for depression. For PTSD, the picture is much thinner, and this is where a lot of public conversation gets ahead of the data.

The most substantial trauma-specific data comes from an open-label Phase 2 study of COMP360, a synthetic psilocybin formulation, in which 22 patients with PTSD received a single 25mg dose. Twenty-five milligrams of synthetic psilocybin is roughly equivalent to 3 to 4 grams of dried Psilocybe cubensis, though the psilocybin content of mushrooms varies considerably by strain and storage, so that equivalence is approximate rather than precise. The study found the dose was well tolerated with no serious adverse events, and reported rapid and durable symptom improvement from baseline through 12 weeks.

That is genuinely encouraging. It is also not what it is often made out to be. An open-label study has no control group, which means everyone knew what they were receiving and there is no way to separate the drug’s effect from expectation, therapist attention, and the natural course of symptoms. The FDA has since accepted an Investigational New Drug application allowing controlled trials of COMP360 for PTSD to proceed. That is the study that will actually answer the question, and it has not reported yet.

There is also a theoretical concern worth exploring. Psilocybin can produce intense and destabilizing experiences, and in a person carrying unprocessed trauma, an experience that opens the material without adequate containment can be harmful rather than healing. This is not an argument against psilocybin for trauma. It is an argument for taking the preparation and support structure seriously, and for treating anyone who dismisses that risk as a poor source of advice.

Our discussion of psilocybin and the current PTSD evidence goes deeper into what the trials do and do not show.

How Do the Three Actually Compare?

Set side by side, the trade-offs become clearer.

Evidence strength: MDMA is the clear leader, with two Phase 3 trials specifically in PTSD populations. Ketamine has multiple small randomized controlled trials. Psilocybin has open-label data and controlled trials underway.

Legal access in the United States: Ketamine is the only one available now, through licensed clinics in every state. MDMA is not approved and is not available outside research settings. Psilocybin is legally accessible for supported adult use in Oregon and Colorado, but those frameworks are not medical treatment programs and are not designed around trauma protocols.

Durability: MDMA aims for lasting change after a short course. Psilocybin’s early trauma data suggests durability out to at least 12 weeks, though from an uncontrolled study. Ketamine typically requires ongoing maintenance.

Experience: MDMA sessions are long, emotionally intense, and cognitively lucid. Psilocybin sessions can be profoundly disorienting and are harder to steer. Ketamine sessions are shorter and often dissociative, which some people find useful and others find alienating.

Risk profile: All three carry cardiovascular considerations and interact with common psychiatric medications, SSRIs in particular. None of them are appropriate for someone with a personal or family history of psychosis or bipolar disorder without careful specialist evaluation. Our guide to contraindications and who should pause first covers the screening questions that matter most.

So What Should Someone with PTSD Actually Do?

The real answer is that the question “what is the best psychedelic for PTSD” is the wrong frame. The better question is what is available, what is appropriate for your specific presentation, and what support structure surrounds whatever you choose.

If you want the treatment with the strongest trauma-specific evidence, that is MDMA, and it is not currently accessible outside of trials. Checking whether you qualify for an ongoing study is a legitimate path.

If you want something you can begin now, ketamine is the realistic option, and the variable that most determines whether it helps is not the drug. It is whether the provider treats it as a psychiatric intervention embedded in trauma-informed care, or as an infusion service.

If you are drawn to psilocybin, the research is early, and the case for waiting for controlled data is stronger here than for the other two. If you proceed anyway, the preparation and integration matter more, not less, precisely because the evidence gives you less to stand on.

Across all three, the pattern in the research is the same. The compounds do not do the work on their own. What produces durable change is the combination of the medicine, a skilled guide, and a serious integration process afterward. That is the part that gets least attention and matters most.